Tests KDS2010 in people with early Alzheimer's disease and memory problems
Tests KDS2010 pills against placebo in adults with early Alzheimer's disease.
Key facts
- Who runs it
- NeuroBiogen Co., Ltd
- Where
- Guri-si, Gwangju, Incheon, Seoul, and Suwon, South KoreaSee the 8 sites
- Trial code
- NCT07027072
- KCT0010589
- Registry title
- Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 114 people, planned
- Started
- 6 Aug 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- KDS2010
- Placebo
- Record updated
- 22 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 to 85 with mild cognitive impairment or mild dementia due to Alzheimer's disease, who also have a caregiver.
- Age
- 50 to 85 years
- Sex
- Men and women
- Disease stage
- Mild cognitive impairment or mild Alzheimer's disease, confirmed at screening. CDR score of 0.5 to 1.0 (memory score at least 0.5). MMSE score of 21 to 30.
- Earlier treatment
- Some Alzheimer's disease drugs must not have been taken in the 12 weeks before screening. Memory drugs such as donepezil or memantine are allowed only at a stable dose for at least 12 weeks before baseline.
- Biomarker or test result
- A positive amyloid PET scan at screening.
Main reasons for not taking part
- Memory problems or dementia caused by something other than Alzheimer's disease
- Pregnant or breastfeeding women
- Cannot have an MRI or PET scan
- Unstable heart disease, or uncontrolled high blood pressure or diabetes
- Taking certain other drugs, such as MAO inhibitors, opioids or many antidepressants
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Male and female adults aged ≥50 and ≤85 years at the time of written consent
- Patients with MCI or mild AD confirmed at screening according to the 2024 diagnostic criteria (APPENDIX 1) of the National Institute on Aging-Alzheimer's Association (NIA-AA)
- Subjects whose total CDR score (CDR-GS) is 0.5 to 1.0 at screening (however, CDR memory score is ≥0.5)
- Subjects with a Mini-Mental State Examination (MMSE) score of 21 to 30 at screening
- Subjects who test positive for amyloid on Positron Emission Tomography (PET) during screening
- Subjects who have a caregiver capable of providing accurate information about the subject's cognitive and functional abilities and appropriate for the planned assessments in the study, as judged by the investigator
- Subjects (or their legal representatives) who have voluntarily agreed to participate in this study and have given written consent
Who cannot take part
- Subjects confirmed during screening to have had the following medical history:; Malignant tumors within five years prior to screening except for basal cell carcinoma, cutaneous squamous cell carcinoma, thyroid cancer, or carcinoma in situ that has not recurred in over three years and is considered successfully treated by the investigator; History of alcohol or drug abuse within two years prior to screening; Loss of consciousness of unknown cause, or seizure within the past 52 weeks before screening; Unstable and clinically significant cardiovascular diseases despite appropriate treatment (acute coronary syndrome (ACS), tachycardia, clinically significant arrhythmias, cardiomyopathy, angina of at least CSS III, heart failure of NYHA II-IV, or clinically significant valvular heart disease) within 24 weeks before baseline; Severe or active infectious diseases requiring antibiotics or antivirals within four weeks before baseline; A history of stroke involving a major vascular area, transient ischemic attack (TIA), epilepsy, or severe head trauma with loss of consciousness; Hypersensitivity or allergy to any components of the investigational product
- Subjects who have undergone or require treatment with the following:; AD disease-modifying agents (aducanumab, lecanemab, donanemab, gantenerumab, solanezumab, blarcamesine, simufilam, tricaprilin, valiltramiprosate, etc.) within 12 weeks before screening; Medications that may improve cognitive abilities or affect AD treatment (AChEIs, donepezil, galantamine, rivastigmine, tacrine, memantine, etc.) within 12 weeks before screening, except if the subject has been on a stable dose for at least 12 weeks before baseline and maintains the same composition/dosage/method of administration during the study period; CNS-active drugs or those affecting cognitive function antidepressants other than serotonergic drugs [e.g., bupropion], sedatives [e.g., carbamazepine], dopamine antagonists [e.g., antipsychotics, metoclopramide], amfepramone, mazindol) within 12 weeks before screening; Central anticholinergics and sedating H1-antihistamines within 12 weeks before screening; However, exceptions are allowed for one-time use of the drugs, such as second-generation H1 antihistamines (e.g., cetirizine, levocetirizine, etc.) or peripheral anticholinergics with no central action (e.g., trospium for treating overactive bladder). But the use is prohibited for at least 3 days from the date of cognitive function evaluation
- Other investigational products or clinical trial devices within four weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)
- Monoamine oxidase inhibitors (MAOIs) and linezolid within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)
- Opioids (pethidine, tramadol, tapentadol, etc.) within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)
- Cyclobenzaprine and St. John's wort within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)
- The following serotonergic drugs within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out),; selective serotonin (5HT1) agonists; lithium; lamotrigine; ritonavir; dapoxetine; Selective serotonin reuptake inhibitors (SSRIs); dapoxetine; Serotonin-norepinephrine reuptake inhibitors (SNRIs); Tricyclic or tetracyclic antidepressants; triazolopyridine antidepressant However, amitriptyline ≤ 50 mg/day, trazodone ≤ 100 mg/day, citalopram ≤ 20 mg/day, and sertraline ≤ 100 mg/day are allowed without washout
- Use of CYP3A4 strong inducer, CYP3A4 strong inhibitor, CYP2D6 strong inducer, and CYP2D6 strong inhibitor during the screening period; Inability to undergo MRI or PET scans; Pregnant or breastfeeding women; Fertile women or men who are unwilling to use effective contraception* from the date of written consent until 12 weeks after the last administration of the investigational product; *Effective contraception is defined as follows, and at least one method should be used:; Hormonal contraception (oral, injectable, implantable, etc.); Intrauterine device (IUD) or system (IUS); Sterilization or surgical procedures (vasectomy, bilateral tubal ligation/surgery, hysterectomy); Dual contraception methods: Simultaneous use of barrier methods (male condoms) with the methods listed above; Absolute abstinence: Total abstinence from sexual intercourse is recognized if the investigator deems the subject's age, occupation, lifestyle, or sexual orientation assures contraception. However, periodic abstinence (calendar method, mucus method, and symptothermal method), withdrawal, and coitus interruptus are not recognized as effective contraception methods; Other conditions deemed by the investigator to be unsuitable for participation in the study
- Cognitive impairment or dementia due to causes other than Alzheimer's disease; Vascular dementia, central nervous system infections (e.g., HIV, syphilis, etc.), head trauma, Creutzfeldt-Jakob disease, Pick's disease, Huntington's disease, Parkinson's disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, thyroid disorders, parathyroid disorders, Vitamin B12 deficiency, folic acid deficiency, other metabolic and nutritional deficiencies, etc; Alcohol or drug abuse, dependence
- Subjects with cognitive impairment due to hypothyroidism, nutritional deficiencies, Vitamin B12 or folic acid deficiency as assessed during screening
- Subjects confirmed during screening to have had the following accompanying disease:; Clinically significant neurological diseases or serious pathological findings affecting cognitive function as confirmed by brain imaging studies within 52 weeks prior to screening, including multiple sclerosis, normal pressure hydrocephalus, brain tumor (however, exceptions are allowed for lesions diagnosed as benign and with a maximum diameter of less than 1 cm), spinal cord infarction, major hemorrhage (defined as having a diameter > 1 cm in MRI) or subdural hemorrhage, cerebral vascular malformation, communicating hydrocephalus, inflammatory demyelinating diseases, etc; Uncontrolled hypertension despite appropriate treatment at screening or baseline (SBP ≥160 mmHg or DBP ≥100 mmHg); Dizziness or fainting when standing due to orthostatic hypotension that may affect the evaluation according to the judgment of the investigator; Uncontrolled diabetes (HbA1c > 9%) during screening, despite appropriate treatment; Bleeding disorders (Platelet <50,000/mm³) during screening, despite appropriate treatment; Patients with severe hepatic impairment (Child-pugh class C) at screening; Following laboratory test values at screening:; AST or ALT > 2.5 x ULN; total bilirubin > 1.5 x ULN (however, in case of Gilbert syndrome, > 3.0 mg/dL); MDRD eGFR < 30 mL/min/1.73 m²; QTcF interval >450 msecs for male or 470 msecs for female(12-lead ECG) during screening; Gastrointestinal diseases that may affect oral administration or absorption (celiac disease, Crohn's disease, intestinal resection, etc.); Gastrointestinal diseases, including gastric and duodenal ulcers, that may affect the safety evaluation according to the judgment of the investigator; Psychiatric diagnosis or symptoms that may interfere with the study (uncontrolled major depression, uncontrolled schizophrenia, uncontrolled bipolar affective disorder, etc.), as assessed by the investigator; Positive responses to items 4 or 5 on the Columbia University Suicide Severity Rating Scale (C-SSRS) during screening; Other conditions deemed by the investigator to potentially affect the outcome of the study
- Use of sympathomimetics (ephedrine, methylphenidate, amphetamine, methamphetamine, lisdexamfetamine, etc.) during the screening period
- Use of Dextromethorphan during the screening period
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Where in South Korea
- Hanyang University Guri HospitalGuri-si, South KoreaContact: Hojin Choi, ProfessorTaking people
- Chonnam National Unversity HospitalGwangju, South KoreaContact: Byeongchae Kim, ProfessorTaking people
- Gachon University Gil Medical CenterIncheon, South KoreaContact: Keehyung Park, ProfessorTaking people
- Asan Medical CenterSeoul, South KoreaContact: Jaesung Lim, ProfessorTaking people
- Hanyang University Seoul HospitalSeoul, South KoreaContact: Heejin Kim, ProfessorTaking people
- Konkuk University Medical CenterSeoul, South KoreaContact: Yeonsil Moon, ProfessorTaking people
- Ajou University HospitalSuwon, South KoreaContact: Soyoung Moon, ProfessorTaking people
- The Catholic University of Korea St. Vincent's HospitalSuwon, South KoreaContact: Yongsoo Shim, ProfessorTaking people
About the trial
What the trial wants to find out
A randomized, double-blind, placebo-controlled, dose-finding Phase 2a clinical trial will be conducted to evaluate the efficacy and safety of KDS2010 in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild dementia due to Alzheimer's disease.
Read full original descriptionShow less
Based on preliminary efficacy observed in the Phase 1 clinical trial, a clinical trial will be conducted in Korea. Eligible patients diagnosed with MCI or mild Alzheimer's disease will be stratified by disease stage (MCI/mild AD) prior to randomization. Subjects will be randomly assigned in a 1:1:1 ratio to either Treatment Group 1, Treatment Group 2, or the Control Group. The investigational product will be administered orally once daily for a duration of 24 weeks. Approximately 114 subjects will be enrolled, including an estimated 20% dropout rate, with 38 subjects assigned to each group (Treatment Group 1, Treatment Group 2, and Control Group).
The objectives of the study are as follows:
1. Efficacy Objectives: Efficacy will be evaluated through changes in cognitive function, self-management, and daily living activities before and after administration of KDS2010. Biomarker analysis in plasma and in cerebrospinal fluid (CSF; optional) will also be conducted to explore treatment efficacy. 2. Safety Objectives: The safety and tolerability will be evaluated after administration of KDS2010. 3. Exploratory Objectives: The efficacy of Treatment Groups 1 and 2 compared to the Control group will be explored through cognitive endpoints (the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13), and the Mini-Mental State Examination (MMSE)), stratified by demographic information, tauopathy, and ApoE4 genes.
Based on nonclinical and Phase 1 clinical data, KDS2010 will be administered orally once daily at two dose levels: 60 mg and 120 mg.
The 3 groups in the trial
- Control Group_PlaceboPlacebo, for comparison
A placebo will be administered orally once daily as two tablets per day for 24 weeks. This group will match the investigational drug in appearance but contain no active ingredients to maintain blinding.
Treatment: Placebo
- Treatment Group 1_KDS2010 60 mgTreatment being tested
KDS2010 60 mg will be administered orally once daily as two tablets per day (one 60 mg KDS2010 tablet and one placebo tablet, 60 mg total) for 24 weeks. This group will receive the active investigational drug to evaluate its safety and efficacy.
Treatment: KDS2010
- Treatment Group 2_KDS2010 120 mgTreatment being tested
KDS2010 60 mg will be administered orally once daily as two tablets per day (two 60 mg KDS2010 tablets, 120 mg total) for 24 weeks. This group will receive the higher dose of the investigational drug to evaluate its safety and efficacy.
Treatment: KDS2010
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease
- Plain-language title
- Tests KDS2010 in people with early Alzheimer's disease and memory problemsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07027072, who can take part
- Record updated
- 22 June 2026